Charlotte C. van Ruiten

Sodium glucose cotransporter-2 inhibitors protect the cardiorenal axis: Update on recent mechanistic insights related to kidney physiology.

D. V. van Raalte, Anne C. Hesp, Charlotte C. van Ruiten, 2022, European journal of internal medicine.

SGLT2 Inhibitors in Combination Therapy: From Mechanisms to Clinical Considerations in Type 2 Diabetes Management

R. IJzerman, L. van Bloemendaal, D. V. van Raalte, 2018, Diabetes Care.

Effect of exenatide twice daily and dapagliflozin, alone and in combination, on markers of kidney function in obese patients with type 2 diabetes: A prespecified secondary analysis of a randomized controlled clinical trial

M. Nieuwdorp, H. Heerspink, R. IJzerman, 2021, Diabetes, obesity & metabolism.

Mechanisms underlying the blood pressure lowering effects of dapagliflozin, exenatide, and their combination in people with type 2 diabetes: a secondary analysis of a randomized trial

M. Nieuwdorp, R. IJzerman, E. Serné, 2022, Cardiovascular Diabetology.

Brain Activation in Response to Low-Calorie Food Pictures: An Explorative Analysis of a Randomized Trial With Dapagliflozin and Exenatide

D. Veltman, M. Nieuwdorp, R. IJzerman, 2022, Frontiers in Endocrinology.

Combination therapy with exenatide decreases the dapagliflozin‐induced changes in brain responses to anticipation and consumption of palatable food in patients with type 2 diabetes: A randomized controlled trial

D. Veltman, M. Nieuwdorp, R. IJzerman, 2022, Diabetes, obesity & metabolism.

Personalized Dietary Advice to Increase Protein Intake in Older Adults Does Not Affect the Gut Microbiota, Appetite or Central Processing of Food Stimuli in Community-Dwelling Older Adults: A Six-Month Randomized Controlled Trial

M. Visser, B. Keijser, R. IJzerman, 2023, Nutrients.

Effects of Dapagliflozin and Combination Therapy With Exenatide on Food-Cue Induced Brain Activation in Patients With Type 2 Diabetes

F. Barkhof, D. Veltman, M. Nieuwdorp, 2022, The Journal of clinical endocrinology and metabolism.